Parabilis Medicines, Inc. (PBLS)
NASDAQ: PBLS · Real-Time Price · USD
31.28
-1.53 (-4.66%)
At close: Jul 24, 2026, 4:00 PM EDT
31.37
+0.09 (0.29%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Parabilis Medicines Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Parabilis Medicines stock has a consensus rating of "Strong Buy" and an average price target of $41.75. The average 1-year stock price forecast is 33.47% higher than the current stock price, while the lowest is $40 (+27.88%) and the highest is $45 (+43.86%).
Price Target: $41.75 (+33.47%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Parabilis Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Initiates $42 | Buy | Initiates | $42 | +34.27% | Jul 18, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $40 | Buy | Initiates | $40 | +27.88% | Jul 6, 2026 |
| Evercore ISI | Evercore ISI | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jul 6, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Initiates $45 | Buy | Initiates | $45 | +43.86% | Jul 6, 2026 |
| Guggenheim | Guggenheim | Buy Initiates $40 | Buy | Initiates | $40 | +27.88% | Jul 6, 2026 |
Financial Forecast
Revenue This Year
16.67M
Revenue Next Year
n/a
from 16.67M
Decreased by -100.00%
EPS This Year
-1.66
EPS Next Year
-1.90
from -1.66
EPS and Forward PE are based on non-GAAP adjusted numbers.